Drug Search Results
More Filters [+]

Tosedostat

Alternative Names: tosedostat, chr-2797
Latest Update: 2023-09-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: APM1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chroma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tosedostat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Myelodysplastic Syndrome|Acute Myeloid Leukemia

Phase 2: Leukemia, Plasma Cell|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Non-Small-Cell Lung Cancer|Preleukemia|Multiple Myeloma|Adenocarcinoma|Pancreatic Cancer|Anemia, Refractory, with Excess of Blasts

Phase 1: Oncology Solid Tumor Unspecified|Healthy Volunteers|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Preleukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-7041-83/hah

N/A

Not yet recruiting

Surgical Wound Infection

2020-05-04

NCI-2018-01817

P1

Terminated

Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia

2019-07-04

LI-1

P3

Unknown status

Acute Myeloid Leukemia|Myelodysplastic Syndrome

2019-05-04

MUK three

P2

Completed

Multiple Myeloma

2017-10-30

Recent News Events